Global Diabetes Market Trends & Future Forecast Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV

Sept. 16, 2011 - PRLog -- Report Details

“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering:

• Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
• Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
• Region wise Diabetes Health Expenditure and Mortality
• Top 10 Countries Diabetes Population and Future Forecast
• Top 5 Countries Diabetes Drug Market and Future Forecast
• Top 7 Countries Insulin Market and Future Forecast
• Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
• Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
• Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
• Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights

• USA controls more than 50% of the total Diabetes Drug market share in 2009
• Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
• China will have the second highest Insulin market share by 2012 replacing Germany
• DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
• GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
• Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
• Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
• Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
• Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
• China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
• Japan Insulin market is expected to be more than US$ 1 Billion by 2010

Data Sources  

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

Contact Us
Ankit Mishra
Relationship Manager
Email: info@renub.com
Phone: +91-120-421-9822, +91-120-254-5750 (India)
      +1-678-302-0700 (USA)

Click here to view the report details: http://renub.com/reports/showdetails.aspx?id=27

For more information visit: http://www.renub.com/

Related Reports: http://renub.com/reports/showdetails.aspx?id=42
               
                      http://renub.com/reports/showdetails.aspx?id=47
 
                               http://renub.com/reports/showdetails.aspx?id=33